BergenBio Fundamentale Forhold (BGBIO)

[TekBot]

BERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2021

Bergen, Norway, 16 February 2022 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical needs, announces its results for the fourth quarter and
…

Vis børsmeldingen

full year 2021.

A briefing by BerGenBio’s senior management team will take place at 10:00am CET
today via a webcast presentation, followed by a Q&A session. Please see below
for details.

Operational Highlights - fourth quarter 2021 (including post-period end)

· Post-period end, BerGenBio announced its participation in the EU-SolidAct
trial, part of EU-RESPONSE, a pan-European research project involved with the
rapid and coordinated investigation of medications to treat COVID-19 during the
ongoing pandemic allowing BerGenBio to potentially confirm encouraging clinical
data at significantly reduced cost.
· Licensed key exclusive intellectual property rights from UT Southwestern
Medical Center, which strengthen the intellectual property estate for the
potential treatment of Non-Small Cell Cancer (NSCLC) patients with STK11
mutations.
· Granted Fast Track designation by the FDA for bemcentinib in combination
with an anti-PD-(L)1 agents as treatment for patients with STK11 altered
advanced/metastatic NSCLC patients without actionable mutations.
· Presented pre-clinical and clinical data on bemcentinib in STK11 mutated
NSCLC at SITC Annual Meeting 2021, indication that bemcentinib restores response
to anti-PD-1 treatments in NSCLC patients with STK11 mutations.
· Presented updated data from Phase II trial (BGBC003) of bemcentinib in
combination with low dose cytarabine (LDAC) in older, relapsed and refractory
AML patients at the 63rd Annual American Society of Hematology (ASH) Meeting.
· Anders Tullgren appointed as Chairman of the Board, bringing over 35 years
of global experience in both large pharmaceutical and small/mid-size biotech
environments.

Financial Highlights - fourth quarter and full year 2021

(Figures in brackets = same period 2020 unless otherwise stated)

· Revenue amounted toNOK 0.8 million (NOK 0.6 million) for the fourth quarter
and NOK 0.8 million (NOK 0.6 million) for the full year 2021
· Total operating expenses for the fourth quarter were NOK 68.1 million (NOK
72.4 million) and total operating expenses for the full year 2021 amounted to
315.2 million (NOK 261.7 million)
· The operating loss for the quarter came toNOK67.3million (NOK71.8million)
and NOK 314.5 million (NOK 261.1 million) for the full year 2021
· Cash and cash equivalents amounted to NOK 436.4 million at the end of
December 2021 (NOK 721.6 million by end of December 2020)

Martin Olin, Chief Executive Officer of BerGenBio, commented: "In the fourth
quarter of 2021 we continued to make significant progress in defining our
strategy and priorities to advance our two AXL development candidates. Our lead
development candidate, bemcentinib, a potentially first-in-class selective AXL
inhibitor currently undergoing Phase II clinical trials in NSCLC, AML and
respiratory infections (COVID-19), is well positioned for further advancement.

"Our strategy and priorities going forward will be anchored within a rigorous
data-driven framework, where the scientific rationale, pre-clinical and clinical
data define a compelling rationale for advancing our development candidates
towards potential treatment modalities addressing high unmet medical needs.

“With a clear strategy in place, I believe BerGenBio is well positioned to
progress and deliver on its potential. I look forward to providing you with
further updates on our progress.”

Presentation and Webcast Details

The live webcast link is available at www.bergenbio.com in the
Investors/Financial Reports section. A recording will be available shortly after
the webcast has finished.

Webcast link:
https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20220216_7

Dial-in numbers:

NO: +47-21-956342

UK: +44-203-7696819

US: +1 646-787-0157

SE: +46-4-0682-0620

DK: +45 78768490

Pin: 712491

The fourth quarter and full year report and presentation will be made available
on the Company’s website in the Investors/Financial Reports section and a
recording of the webcast will be made available shortly after the webcast has
finished.

-Ends-

Contacts

Martin Olin
Chief Executive Officer, BerGenBio ASA
ir@bergenbio.com

Rune Skeie
Chief FinancialOfficer, BerGenBio ASA
rune.skeie@bergenbio.com

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

ConsiliumStrategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

AboutBerGenBioASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer and COVID
-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is
undergoing phase I clinical testing. In parallel, BerGenBio is developing a
potential companion diagnostic test to identify patient populations most likely
to benefit from AXL inhibition: this is expected to facilitate more efficient
registration trials supporting a precision medicine-based commercialisation
strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit? www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies, and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

BerGenBio ASA: Increase of share capital, exercise of share options

Bergen, Norway, 16 February 2022

The Board of Directors in BerGenBio ASA (the"Company") (OSE: BGBIO) have, to
…

Vis børsmeldingen

fulfil the Company’s obligations under the share option agreements and in
accordance with the authorization granted by the general meeting on 19 March
2021, resolved to increase the Company’s share capital by NOK 10,507.70 by
issuance of 105,277 new shares. The new shares are subscribed for by option
owners who wishes and are entitled to exercise options in accordance with the
Company’s option scheme. Each option gives a right to receive one share in the
Company. The subscription price is in accordance with the prevailing options
price pursuant to the Company´s option scheme, in average NOK 16.01 per share.

The capital increase is expected to be registered within 7 days, and following
the issuance of the new shares, the issued share capital of BerGenBio ASA will
be NOK 8,866,053.20 consisting of 88,660,532, each with a par value of NOK 0.10.

-End-

Contacts

Martin Olin

CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie

CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[vcp]

Mulig jeg har sovet i timen, men denne var int. og kan være verd å dykke litt i.

« drug-induced expression of AXL

[vcp]

Samme jeg fant i går, er en del studier som har funnet samme. Styrker muligheten for kombinasjon.

[TekBot]

BerGenBio ASA: Share capital increase

Bergen, Norway, 22 February 2022 - Reference is made to the stock exchange
notice published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 16 February
2022 where the Company announced that the board of directors of the Company had
…

Vis børsmeldingen

resolved to increase the Company’s share capital in connection with the exercise
of options pursuant to the Company’s share option program. A total of 105,277
options were exercised and 105,277 new shares were issued at an average
subscription price of NOK 16.01 per share.

The share capital increase has been duly registered in the Norwegian Register of
Business Enterprises. Following such registration, the Company’s share capital
is NOK 8,866,053.20 divided into 88,660,532 shares, each with a nominal value of
NOK 0.10.

-End-

Contacts

Martin Olin

CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie

CFO, BerGenBio ASA

Rune.skeie@bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[Tekspert]

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

1. @anon28800809 (762 likes)

@anon28800809

I forbindelse med at jeg fikk en PM fra en forumbruker, sjekket jeg samtidig hva som var blitt postet siden sist. Jeg ser det er postet noen innlegg i forbindelse med at jeg sa “takk for meg”, og vil benytte anledningen til å gi en siste avklaring:

2. @vcp (160 likes)

@vcp

Topp og the pop i dette markedet, greit å få det bekreftet av 3 part. Selskapet har hevdet sin posisjon, så lenge jeg kan huske

3. @Direkte (104 likes)

@Direkte

Hei, da har jeg vært i kontakt med selskapet angående covid studie( hvilken fase)

Resten av topp 10:

4. @Matadoren (97 likes)

5. @PankPinter (69 likes)

6. @Hayen (65 likes)

7. @drdr (63 likes)

8. @Boms (54 likes)

9. @Roc (52 likes)

10. @Realize_1 (36 likes)

Gratulerer!

[TekBot]

BERGENBIO TO PRESENT AT CARNEGIE VIRTUAL NORDIC HEALTHCARE SEMINAR

Bergen, Norway, 17 March 2022 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical needs, is pleased to announce that CEO Martin Olin will be
…

Vis børsmeldingen

presenting at the Carnegie Virtual Nordic Healthcare Seminar taking place today
at 15:15 CET.

The presentation will be made available on the Company’s website in the
Investors section shortly after the presentation.

-Ends-

Contacts

Martin Olin
Chief Executive Officer, BerGenBio ASA
ir@bergenbio.com

Rune Skeie
Chief FinancialOfficer, BerGenBio ASA
rune.skeie@bergenbio.com

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

ConsiliumStrategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

AboutBerGenBioASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer and COVID
-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is
undergoing phase I clinical testing. In parallel, BerGenBio is developing a
potential companion diagnostic test to identify patient populations most likely
to benefit from AXL inhibition: this is expected to facilitate more efficient
registration trials supporting a precision medicine-based commercialisation
strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit? www.bergenbio.com

Kilde

[TekBot]

BERGENBIO ANNOUNCES PUBLICATION IN CELL REPORTS MEDICINE JOURNAL INDICATING EFFICACY OF BEMCENTINIB IN STK11/LKB1 LUNG CANCER POPULATION

The article identifies the key role of AXL inhibition in restoring response to
immune checkpoint blockade therapy in lung cancer with mutations in the
STK11/LKB1 gene
…

Vis børsmeldingen

Bergen, Norway - 17 March 2022- BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL inhibitors for severe
unmet medical needs, today announces the publication of a peer-reviewed article
entitled “AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant
NSCLC through expansion of TCF1+ CD8+ T cells” in the journalCell Reports
Medicine.

The article reports on research that identifies AXL as a critical targetable
driver of immune suppression in STK11/LKB1 mutated non-small cell lung cancer
(NSCLC). Mutations in STK11/LKB1 in NSCLC occur in approximately 20% of patients
and are associated with poor outcomes and limited response to immune checkpoint
blockade, commonly utilized treatments for lung cancer.

This article and its accompanying material are accessible here:

https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(22)00060
-X (Error during processing.
m%2Fcell-reports-medicine%2Ffulltext%2FS2666-3791(22)00060
-X&data=04%7C01%7Crune.skeie%40bergenbio.com%7Cb59bc32cca894be7b28c08da0745f8c4%7
C2b50b422ca6d42af9fc0741b248bb071%7C0%7C0%7C637830294373647052%7CUnknown%7CTWFpbG
Zsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&s
data=tLI4UnfigSyr29CNzY39A0Pfeugajy9AT6I%2Bu%2BXHUVI%3D&reserved=0)

The research was led by Professor Rolf A. Brekken, in the Hamon Center for
Therapeutic Oncology Research at the UT Southwestern Medical Center. The group
introduced a STK11/LKB1 mutation into a preclinical murine model of lung
adenocarcinoma, resulting in immune checkpoint blockade refractory tumors. The
group posits that the lack of response occurred because the STK11/LKB1 mutated
tumors lacked a specific population of immune cells (TCF1-expressing CD8+ immune
T cells). This immune cell population was also reduced in human NSCLC tumors
carrying STK11/LKB1 mutations.

Systemic inhibition of AXL by the BerGenBio molecule bemcentinib led to
increased type I interferon secretion from AXL-expressing dendritic cells,
resulting in expansion of the TCF1+ T cell population and restored therapeutic
response to immune checkpoint blockade treatment. These results were observed in
both an immunocompetent mouse model and in mice bearing human STK11/LKB1 mutant
NSCLC tumors along with a humanized immune system. The paper also summarizes
clinical data in NSCLC patients with identified STK11/LKB1 mutations receiving
bemcentinib and immune checkpoint blockage (pembrolizumab), who demonstrated
objective clinical response to combination therapy.

In November 2021 BerGenBio announced that the U.S. Food and Drug Administration
(FDA) granted Fast Track designation for bemcentinib in combination with an anti
-PD-(L)1 agent as a treatment for patients with STK11/LKB1 altered
advanced/metastatic NSCLC patients without actionable mutations.

Martin Olin, Chief Executive Officer of BerGenBio, commented: “We are pleased to
receive this strong preclinical validation of the potential role of bemcentinib
to treat STK11/LKB1 mutated NSCLC patients. Data suggests that this significant
patient population is underserved by current immune checkpoint blockade
therapies, and we hope that the combination with bemcentinib can restore the
immune response in these patients. The identification of a new druggable
biomarker segment such as the STK11/LKB1 mutations may offer significant hope
for improved patient outcomes in combination with the current standard of care
therapies. We look forward to initiating a clinical trial this year to advance
bemcentinib into development for this patient population.”

Contacts:

For BerGenBio: Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Consilium Strategic
Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer and COVID
-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is
undergoing phase I clinical testing. In parallel, BerGenBio is developing
companion diagnostic tests to potentially identify patient populations most
likely to benefit from AXL inhibition: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Suchrisks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[srh]

Noen som kan oversette dette til et menneskelig språk- i kortformat?

[vcp]

Kort fortalt; Bra potensiale innenfor et gigantisk marked.

BgBio har allerede fått FDA Fast track her, etter respons i en NSCLC subgruppe.

Subgruppen utgjør ca; 20% av dette markedet:

Konventet den summen til nok

[Fornybar]

Systemic inhibition of AXL by the BerGenBio molecule bemcentinib led to
increased type I interferon secretion from AXL-expressing dendritic cells,
resulting in expansion of the TCF1+ T cell population and restored therapeutic
response to immune checkpoint blockade treatment. These results were observed in
both an immunocompetent mouse model and in mice bearing human STK11/LKB1 mutant
NSCLC tumors along with a humanized immune system. The paper also summarizes
clinical data in NSCLC patients with identified STK11/LKB1 mutations receiving
bemcentinib and immune checkpoint blockage (pembrolizumab), who demonstrated
objective clinical response to combination therapy.

Når du gir BEM til en pasient øker utskillelse av Type 1 interferon (et stoff som er viktig for at immunforsvaret skal gi respons) fra dendritiske celler som uttrykker AXL. Dendritiske celler er en del av immunforsvaret, og disse ønsker du at skal være parat til å ta opp antigener og å lære opp T-celler til å angripe farlige ting. Det førte til en økning av T-celler og en gjenopprettet terapeutisk respons med sjekkpunkthemmere, dvs at immunforsvaret begynte å fungere igjen da de også gav sjekkpunkthemmere.

Disse forsøkene gjorde de i mus med friskt immunforsvar og i mus innsatt med STK11-mutert NSCLC (lungekreft) og innsatt menneskelig immunceller.

I tillegg har de sett på data fra pasienter i de andre lungekreftstudiene med bekreftet STK11-mutasjon.

[BillyP]

Så et marked på NOK 70 milliarder på sikt. Hvs målgruppen utgjør 20% av tilfellene. Korrekt?

[vcp]

Blir vel det, jeg ser det er litt varierende tall.
Om en er litt konservativ kan en si 50 milliarder, årlig

Får de gode nok resultater her, så står nok BP klar med en fin sum.

Men de køddene venter til moden data + så jeg forventer ikke avtale med det første.
Men et studie samarbeid er ikke helt utenkelig. De har en del av dem i pipen allerede.

Når jeg først er inne på det, hvor stor del av pipen er priset inn på det kursnivået en ser nå?
Enten vet noen, noe vi burde vist eller så er det ikke mye som er verdsatt.

Bare at familien Mohn er største eier er verd et par milliarder. Lol😄

[Realize_1]

[Tekspert]

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

1. @vcp (181 likes)

@vcp

Topp og the pop i dette markedet, greit å få det bekreftet av 3 part. Selskapet har hevdet sin posisjon, så lenge jeg kan huske

2. @Matadoren (125 likes)

@Matadoren

3. @Direkte (80 likes)

@Direkte

Hei, da har jeg vært i kontakt med selskapet angående covid studie( hvilken fase)

Resten av topp 10:

4. @PankPinter (77 likes)

5. @Hayen (55 likes)

6. @romaper (47 likes)

7. @drdr (35 likes)

8. @Bonus (31 likes)

9. @OpulentusTT (31 likes)

10. @Boms (23 likes)

Gratulerer!

[TekBot]

BERGENBIO ASA: BOARD APPROVAL OF 2021 ANNUAL FINANCIAL STATEMENT AND ANNUAL REPORT 2021

Bergen, Norway - 7 April 2022- BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL inhibitors for severe
unmet medical needs, announces that the Board of Directors today approved the
…

Vis børsmeldingen

2021 Annual Financial Statements prepared in accordance with International
Financial Reporting Standards (IFRS).

The Annual Report for 2021 and ESEF file are attached to this release and are
also available on BerGenBio ASA’s website
Financial Reports - BerGenBio

Contacts:

For BerGenBio: Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer and COVID
-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is
undergoing phase I clinical testing. In parallel, BerGenBio is developing
companion diagnostic tests to potentially identify patient populations most
likely to benefit from AXL inhibition: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

BERGENBIO ASA: NOTICE OF ANNUAL GENERAL MEETING

Bergen, Norway - 7 April 2022: BerGenBio ASA (OSE:BGBIO) will be holding its
Annual General Meeting virtually on 28 April 2022 at 10:00 hours (CEST).

…

Vis børsmeldingen

The notice, power of attorney and proposal from Nomination Committee are
attached to this release. The notice will be sent to all registered shareholders
and is available on the Company’s website:
General Meetings - BerGenBio

All shareholders are encouraged to exercise their shareholder rights, either
through advance electronically voting through VPS Investor Services, by using
the enclosed proxy form to provide proxy to the Chairman Anders Tullgren (or the
person he appoints), or to attend the general meeting virtually.
Advance vote or proxy for the Annual General Meeting can be registered through
the company’s website or VPS Investor Service within 25 April 2022 16:00 hours
(CEST). Virtual participants need to be logged in to the meeting before 10:00
hours (CEST) 25 April 2022.

All shareholders will receive a reference number and a pin code required for
registration through the company’s website. Reference number and pin code will
be received either by VPS Investor Service or by post depending if the
shareholder is registered as electronical user.
We encourage all shareholders to register as electronical user in VPS.

• END -

AboutBerGenBioASA

BerGenBiois a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate,bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broadphase II clinical development programme
focused on combination and single agent therapy in lung cancer, leukaemia and
COVID-19. A first-in-class functional blocking anti-AXL antibody,tilvestamab, is
undergoingphase I clinical testing. In parallel,BerGenBiois developingacompanion
diagnostic test to identify patient populations most likely to benefit
frombemcentinib: this is expected to facilitate more efficient registration
trials supporting a precision medicine-based commercialisation strategy.

BerGenBiois based in Bergen, Norway with a subsidiary in Oxford, UK. The company
is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information,
visit?www.bergenbio.com

Contacts

Martin Olin, CEO, BerGenBio ASA
ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

BerGenBio strengthens its leadership team with appointment of Cristina Oliva as Chief Medical Officer

Bergen, Norway, 11 April 2022 - BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL inhibitors for severe
unmet medical needs, today announces the appointment of Cristina Oliva, MD as
…

Vis børsmeldingen

Chief Medical Officer (CMO), effective 25 April 2022. Cristina joins the senior
leadership team heading up clinical development of BerGenBio’s selective AXL
inhibitor programs.

Cristina is a Board-certified oncologist and brings over 20 years of senior
clinical development experience across large pharmaceutical, biotechnology and
Clinical Research Organizations (CROs). Most recently Cristina was Vice
President, Oncology and Head of Oncology Centre of Excellence at IQVIA Ltd,
where she led the development of decentralized trials and established and led
the IQVIA Oncology Global Scientific Advisory Board. Prior to her role at IQVIA,
Cristina held senior positions leading oncology development programs for Nordic
Nanovector, Takeda Pharmaceuticals, GlaxoSmithKline and Eli Lilly.

Martin Olin, Chief Executive Officer of BerGenBio, commented: “I’m delighted to
welcome Cristina as our new Chief Medical Officer. Cristina’s leadership
experience within oncology drug development across big pharma, biotech and CRO
environments will be instrumental in executing BerGenBio’s development strategy
for our AXL inhibitor programs, including our most advanced program bemcentinib,
currently in phase II trials.”

On her appointment as Chief Medical Officer at BerGenBio, Cristina Oliva, MD,
commented:“BerGenBio is on the frontier of developing novel, highly selective
AXL inhibitors for the treatment of severe diseases such as oncology and
respiratory infections. I’m very excited to join BerGenBio at this critical
phase and look forward to working with the senior leadership team to help
further advance its AXL inhibitor programs.”

Contacts:

For BerGenBio: Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer and COVID
-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is
undergoing phase I clinical testing.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Suchrisks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

BERGENBIO PRESENTS BEMCENTINIB COVID-19 CLINICAL TRIAL DATA AT ECCMID 2022

Bergen, Norway, 25 April 2022 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL inhibitors for severe
unmet medical needs, announces that it is presenting data today from its Phase
…

Vis børsmeldingen

IIa bemcentinib COVID-19 clinical trial (BCBC020) in a poster presentation at
the 32nd European Congress of Clinical Microbiology and Infectious Diseases
(ECCMID), being held both online and in-person in Lisbon, Portugal, from April
23-26, 2022.

The poster presentation will share findings from the Company’s Phase IIa open
label study of 115 patients evaluating bemcentinib in combination with Standard
of Care (SoC) compared to a SoC control arm in the treatment of moderate to
severe COVID-19 patients, immediatelyafter hospital admission (BGBC020).

Clinical data from the study show that bemcentinibtreatment (up to 14 days)
confers early and sustained protection, limiting clinical deterioration in
patients. Bemcentinib treated patients were discharged earlier from the
hospital, required less supplementary oxygen and demonstrated a significant
reduction in the need for intubation or ventilation.

Biomarker analysis demonstrates that treatment with bemcentinibreduced markers
of acute inflammation and profibrotic cytokines, and increased expression of
protective factors. These changes were more pronounced in patients with more
serious disease, determined by high C-Reactive Protein (CRP) rates, high
neutrophil to lymphocyte ratio (N/L) ratio or increased oxygen usage.

Preclinical data is also being presented from in vitro studies in lung
epithelial cells on bemcentinib’s activity on variants of concern. These data
suggest that bemcentinib inhibits infection of multiple SARS-CoV-2 variants,
including Omicron, building on previous preclinical research from the Company.

Martin Olin, CEO of BerGenBio, commented: “The data we are presenting at ECCMID
today further demonstrates the effectiveness of bemcentinib as a treatment for
severe respiratory infections such as COVID-19. We have been pleased to see
bemcentinib’s impact on reducing disease deterioration in patients. In addition,
we’re encouraged to see that bemcentinib exerts a broad anti-inflammatory and
pro-repair effect on blood biomarkers. We look forward to the initiation of the
EUSolidAct platform trial which will further assess bemcentinib in hospitalised
COVID-19 patients.”

Details of today’s poster presentation are as follows:

Abstract: 04778: Bemcentinib modulation of inflammatory, fibrotic and tissue
repair pathways correspond with favourable clinical outcomes in hospitalised
COVID-19 patients demonstrating higher severity cues: a biomarker perspective

Session Name: 12c. Clinical features, case management, outcome (incl long-term):
programme no. L0383

Time, Location: Monday, 25th April 2022, 12:00pm - 13:00pm (WEST)

-End-

Contacts:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer and COVID
-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is
undergoing phase I clinical testing.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Suchrisks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

BERGENBIO ANNOUNCES COMPLETE DATA ANALYSIS OF ACCORD2 PHASE II BEMCENTINIB STUDY IN HOSPITALIZED COVID-19 PATIENTS - PRIMARY EFFICACY ENDPOINT MET

Complete data analysis confirms that the primary endpoint of improved clinical
response and key secondary endpoints were met in a subprotocol under the
platform ACCORD2 study where bemcentinib was added to standard of care therapy
…

Vis børsmeldingen

BerGenBio to confirm the ACCORD2 data by progressing bemcentinib into EU
-SolidAct, a pan-European platform COVID-19 study enrolling up to 500 patients

Bergen, Norway,April 26, 2022 - BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL inhibitors for severe
unmet medical needs, announced today that a complete data analysis of a
randomized phase II study of bemcentinib in combination with standard of care
(SoC) therapy, ACCORD2 (BGBIL019), in hospitalized COVID-19 patients confirms
that the primary efficacy endpoint was met.

At the July 2021 European Congress of Clinical Microbiology & Infectious
Diseases (ECCMID) meeting, the Company previously presented preliminary data
from the ACCORD2 study in combination with a second COVID-19 study (BGBC020)
showing evidence of therapeutic benefit on meaningful clinical endpoints in a
total of 177 patients. Today’s announcement is the first time complete ACCORD2
data in a total of 61 treated patients has been separately reported.

Overall, 90% of patients treated with bemcentinib + SoC (26 of 29) experienced a
clinical response by day 29 (median 7.0 days), as defined by either a two-point
improvement in World Health Organization (WHO) category from baseline score, or
discharge from hospital, whichever arose sooner. This compared to 69% (22 of 32
patients) with a clinical response to SoC treatment alone (median 9.5 days),
showing statistical significance.

The data was generated under a sub-protocol of the platform ACCORD2 study
(ACCORD2; EudraCT 2020-001736-95 - BGBIL019), a multi-center phase II randomized
study designed to assess the efficacy and safety of candidate agents as add-on
therapies to SoC for the treatment of COVID-19 in hospitalized patients.

Overall, 98% of patients received dexamethasone or an equivalent steroid in
their SoC, and 18% received immunomodulatory treatment with tocilizumab. The
antiviral remdesivir was used in 53% of those randomized to SoC alone, and in
21% of patients treated with bemcentinib.

In addition, key secondary endpoints saw statistically significant improvements
for the bemcentinib + SoC arm compared to SoC alone, including avoidance of any
deterioration by ?1-point increase in WHO score (including death) and ventilator
-free survival over 29 days. At day 29, 97% of bemcentinib + SoC treated
patients were alive compared to 81% of SoC-alone.

Bemcentinib treatment was well tolerated in this patient population, with no
clinically relevant safety signals in comparison to standard of care treatment.

These latest results underline bemcentinib’s potential in COVID-19 and other
severe respiratory infections. As previously announced, bemcentinib will be
studied in the EU-SolidAct trial in up to 500 hospitalized COVID-19 patients.

Professor Tom Wilkinson MA Cantab MBBS PhD FRCP FERS, Professor of Respiratory
Medicine and Chief Investigator on the ACCORD program commented:“With COVID-19
still driving hospital admissions globally it is key that new, more effective
treatments are being developed. These results from the ACCORD2 program indicate
that bemcentinib has demonstrated real promise as a new therapeutic option for
hospitalized patients and it now warrants testing in larger studies. These
results are a testament to the great collaboration between the NHS, NIHR, the
MEU and our Southampton research teams with more exciting results to follow from
the platform.”

Martin Olin, Chief Executive Officer of BerGenBio, commented:“We are highly
encouraged by the final data from our ACCORD2 study in hospitalized COVID-19
patients. The ability of bemcentinib to add a statistically significant benefit
in clinical response over standard of care therapy is promising. We look forward
to moving to the next step in the development of bemcentinib for COVID-19
through our participation in the EUSolidAct platform study, designed to enrol up
to 500 hospitalized COVID-19 patients.”

Contacts:

For BerGenBio: Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

Consilium Strategic Communications

bergenbio@consilium-comms.com
+44 20 3709 5700

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer and COVID
-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is
undergoing phase I clinical testing.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

About ACCORD2 study

Under the bemcentinib sub-protocol of the ACCORD2 study, patients were enrolled
within a calendar day after being admitted to hospital. Eligible patients were
categorized by the WHO 9-point clinical scale and ranged from patients who did
not require supplementary oxygen (grade 3) to those requiring non-invasive
ventilation or high-flow nasal oxygen, but not intubated (grade 5). In the
bemcentinib sub-protocol 29 patients were randomized and received bemcentinib
treatment in addition to SoC.

For further details: A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients - Full Text View - ClinicalTrials.gov

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Suchrisks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 of the Norwegian Securities Trading Act.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 of the Norwegian Securities Trading Act.

Kilde